CN112262139B - 作为激酶抑制剂的氨基吡咯并三嗪 - Google Patents
作为激酶抑制剂的氨基吡咯并三嗪 Download PDFInfo
- Publication number
- CN112262139B CN112262139B CN201980019863.4A CN201980019863A CN112262139B CN 112262139 B CN112262139 B CN 112262139B CN 201980019863 A CN201980019863 A CN 201980019863A CN 112262139 B CN112262139 B CN 112262139B
- Authority
- CN
- China
- Prior art keywords
- triazin
- amino
- pyrrolo
- trifluoromethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622415P | 2018-01-26 | 2018-01-26 | |
| US62/622,415 | 2018-01-26 | ||
| PCT/US2019/014918 WO2019147782A1 (en) | 2018-01-26 | 2019-01-24 | Aminopyrrolotriazines as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112262139A CN112262139A (zh) | 2021-01-22 |
| CN112262139B true CN112262139B (zh) | 2023-07-25 |
Family
ID=65363405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980019863.4A Active CN112262139B (zh) | 2018-01-26 | 2019-01-24 | 作为激酶抑制剂的氨基吡咯并三嗪 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11618753B2 (https=) |
| EP (1) | EP3743430B1 (https=) |
| JP (1) | JP7307734B2 (https=) |
| KR (1) | KR102759231B1 (https=) |
| CN (1) | CN112262139B (https=) |
| AR (1) | AR114186A1 (https=) |
| AU (1) | AU2019211382B2 (https=) |
| BR (1) | BR112020014516A2 (https=) |
| CA (1) | CA3088548A1 (https=) |
| EA (1) | EA202091777A1 (https=) |
| ES (1) | ES2959399T3 (https=) |
| IL (1) | IL276269A (https=) |
| MX (1) | MX2020007531A (https=) |
| SG (1) | SG11202007035YA (https=) |
| TW (1) | TW201940485A (https=) |
| WO (1) | WO2019147782A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3580220B1 (en) | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| DK3704118T3 (da) | 2017-10-30 | 2022-03-14 | Bristol Myers Squibb Co | Aminoimidazopyrazin som kinasehæmmere |
| EP3849969B1 (en) | 2018-09-13 | 2023-04-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| EP3849968B1 (en) | 2018-09-13 | 2022-12-21 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| WO2021067654A1 (en) | 2019-10-03 | 2021-04-08 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| KR20220139947A (ko) * | 2020-02-07 | 2022-10-17 | 샌트랄 글래스 컴퍼니 리미티드 | 경화성 조성물, 경화물, 전자 디바이스, 표시 장치, 광학 부재, 중합체, 감광성 조성물, 패턴 및 화합물 |
| WO2022007921A1 (zh) * | 2020-07-10 | 2022-01-13 | 北京范恩柯尔生物科技有限公司 | 三嗪类化合物及其组合物和用途 |
| CN111925345B (zh) * | 2020-08-21 | 2023-09-29 | 上海科利生物医药有限公司 | 一种手性2-氨甲基四氢呋喃的制备方法 |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| CN116745361A (zh) * | 2021-02-10 | 2023-09-12 | 中央硝子株式会社 | 树脂组合物、树脂膜、基材、聚合物以及聚合性单体 |
| CN113563214B (zh) * | 2021-07-06 | 2024-02-02 | 山东鲁泰控股集团有限公司石墨烯高分子复合材料研发中心 | 一种氨基乙酸的合成方法 |
| CN113527220A (zh) * | 2021-07-26 | 2021-10-22 | 京博农化科技有限公司 | 一种脱硫丙硫菌唑异构体的合成方法 |
| CN114989079B (zh) * | 2022-06-21 | 2023-06-23 | 中国药科大学 | Ripk1激酶靶点抑制剂及其医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| ES2365869T3 (es) * | 2005-11-17 | 2011-10-11 | OSI Pharmaceuticals, LLC | COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR. |
| PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| WO2007064931A2 (en) | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| GB2467670B (en) * | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| IL266563B (en) | 2009-10-06 | 2022-09-01 | Millennium Pharm Inc | Heterocyclic compounds useful as pdk1 inhibitors |
| WO2011123493A1 (en) * | 2010-03-31 | 2011-10-06 | Bristol-Myers Squibb Company | Substituted pyrrolotriazines as protein kinase inhibitors |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| EP3054955B1 (en) | 2013-10-11 | 2018-05-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| ES2807785T3 (es) | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
| KR102483020B1 (ko) | 2016-03-28 | 2023-01-04 | 인사이트 코포레이션 | Tam 저해제로서의 피롤로트리아진 화합물 |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| EP3580220B1 (en) | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| DK3704118T3 (da) | 2017-10-30 | 2022-03-14 | Bristol Myers Squibb Co | Aminoimidazopyrazin som kinasehæmmere |
| EP3849968B1 (en) | 2018-09-13 | 2022-12-21 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| EP3849969B1 (en) | 2018-09-13 | 2023-04-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
-
2019
- 2019-01-24 SG SG11202007035YA patent/SG11202007035YA/en unknown
- 2019-01-24 JP JP2020540798A patent/JP7307734B2/ja active Active
- 2019-01-24 CN CN201980019863.4A patent/CN112262139B/zh active Active
- 2019-01-24 EA EA202091777A patent/EA202091777A1/ru unknown
- 2019-01-24 US US16/963,886 patent/US11618753B2/en active Active
- 2019-01-24 BR BR112020014516-5A patent/BR112020014516A2/pt not_active Application Discontinuation
- 2019-01-24 CA CA3088548A patent/CA3088548A1/en active Pending
- 2019-01-24 AR ARP190100156A patent/AR114186A1/es unknown
- 2019-01-24 ES ES19704524T patent/ES2959399T3/es active Active
- 2019-01-24 WO PCT/US2019/014918 patent/WO2019147782A1/en not_active Ceased
- 2019-01-24 KR KR1020207024141A patent/KR102759231B1/ko active Active
- 2019-01-24 AU AU2019211382A patent/AU2019211382B2/en not_active Ceased
- 2019-01-24 EP EP19704524.8A patent/EP3743430B1/en active Active
- 2019-01-24 MX MX2020007531A patent/MX2020007531A/es unknown
- 2019-01-25 TW TW108102873A patent/TW201940485A/zh unknown
-
2020
- 2020-07-24 IL IL276269A patent/IL276269A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091777A1 (ru) | 2020-10-14 |
| TW201940485A (zh) | 2019-10-16 |
| KR20200115550A (ko) | 2020-10-07 |
| CA3088548A1 (en) | 2019-08-01 |
| ES2959399T3 (es) | 2024-02-26 |
| IL276269A (en) | 2020-09-30 |
| MX2020007531A (es) | 2020-09-09 |
| JP7307734B2 (ja) | 2023-07-12 |
| BR112020014516A2 (pt) | 2020-12-08 |
| SG11202007035YA (en) | 2020-08-28 |
| EP3743430B1 (en) | 2023-08-02 |
| KR102759231B1 (ko) | 2025-01-22 |
| AU2019211382B2 (en) | 2022-06-16 |
| US20200347071A1 (en) | 2020-11-05 |
| EP3743430A1 (en) | 2020-12-02 |
| US11618753B2 (en) | 2023-04-04 |
| WO2019147782A1 (en) | 2019-08-01 |
| AR114186A1 (es) | 2020-07-29 |
| CN112262139A (zh) | 2021-01-22 |
| AU2019211382A1 (en) | 2020-09-17 |
| JP2021511363A (ja) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112262139B (zh) | 作为激酶抑制剂的氨基吡咯并三嗪 | |
| US12157733B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
| KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| EP3704118B1 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| CN112673000B (zh) | 作为受体相互作用蛋白激酶1抑制剂(ripk1)的1h-吲唑甲酰胺 | |
| TW202233614A (zh) | 作為激酶抑制劑之三唑并吡啶化合物 | |
| WO2020116662A1 (ja) | シクロアルカン−１，３−ジアミン誘導体 | |
| RU2830173C2 (ru) | Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы | |
| EA042342B1 (ru) | Аминопирролотриазины в качестве ингибиторов киназы | |
| TW202409011A (zh) | 人類呼吸道融合病毒及間質肺病毒抑制劑 | |
| EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |